Skip to content
lifestyle.folsomlocalnews.com/
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Amneal Pharmaceuticals LLC
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
July 17, 2026
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations
July 17, 2026
Amneal to Report Second Quarter 2026 Results on July 30, 2026
July 9, 2026
Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations
June 29, 2026
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson’s Disease
June 5, 2026
Amneal Announces U.S. FDA Approval of Romidepsin Injection Solution
June 5, 2026
Amneal Reports First Quarter 2026 Financial Results
May 7, 2026
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
April 22, 2026
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
April 22, 2026
Amneal Announces Additional Positive Interim Phase 4 ELEVATE-PD Results with CREXONT® for Parkinson’s Disease, Including Over 3 More Hours of Daily “Good On” Time When Switching from RYTARY®
April 20, 2026
1
2
Next Page
→